Showing 1551-1560 of 1869 results for "".
- Schwind Eye-Tech-Solutions Announces Management Changeshttps://modernod.com/news/schwind-eye-tech-solutions-announces-management-changes/2481149/Rolf Schwind, who was serving as CEO of Schwind eye-tech-solutions GmbH, has withdrawn from active leadership of the company, effective October 1, 2022, and joined the Advisory Board. In that capacity he will continue to contribute to the growth of Schwind with his more than 40 years of
- Foundation Fighting Blindness Announces Leadership Changeshttps://modernod.com/news/foundation-fighting-blindness-announces-leadership-changes/2480924/The Foundation Fighting Blindness announced the promotions of Jason Menzo to chief executive officer of the Foundation, and Russell Kelley, PhD, MBA, to managing director of the Retinal Degeneration (RD) Fund, the venture arm of the Foundation, effective Ju
- Several Changes Made in Leadership of Allergan Eye Carehttps://modernod.com/news/several-changes-made-in-leadership-of-allergan-eye-care/2480578/
- New England College of Optometry to Launch Hybrid OD Teaching and Training Programhttps://modernod.com/news/new-england-college-of-optometry-to-launch-hybrid-od-teaching-and-training-program/2480337/
- First-Hand Accounts From ODs Who Tested Positive With COVID-19https://modernod.com/news/first-hand-accounts-from-ods-who-tested-positive-with-covid-19/2477530/
- Study Probes ODs’ Attitudes About Blue-Light Blocking Deviceshttps://modernod.com/news/study-probes-ods-attitudes-about-blue-light-blocking-devices/2476599/A recent study found that optometrists remain split on the impact of blue light from electronic devices, such as computer and phone screens, and the effectiveness of blue light-blocking devices, according to reporting by Patrick Campbell in MD Magazine, as
- MediPrint Ophthalmics Unveils Phase 2b Trial Results for Drug-Eluting Contact Lens in Glaucoma Treatmenthttps://modernod.com/news/mediprint-ophthalmics-unveils-phase-2b-trial-results-for-drug-eluting-contact-lens-in-glaucoma-treatment/2482539/MediPrint Ophthalmics announced positive results from its phase 2b clinical trial of its 3D-printed, drug-eluting contact lens LL-BMT1. The results, presented by Ian Ben Gaddie, OD, FAAO, at the Ameri
- American Academy of Optometry Announces the 2023 Garlan W. Clay Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-the-2023-garlan-w-clay-award-recipients/2481798/The American Academy of Optometry has announced the recipients of the 2023 Garland W. Clay award: From the College of Optometry, The Ohio State University, Columbus, Ohio: Donald O. Mutti, OD, PhD, FAAO Loraine T. Sinnott, PhD G. Lynn Mitchel
- Bryan Wolynski Named Chief Technology Officer at Lighthouse Guildhttps://modernod.com/news/bryan-wolynski-named-chief-technology-officer-at-lighthouse-guild/2480702/Bryan Wolynski, OD, FAAO, has been named Chief Technology Officer at Lighthouse Guild. Dr. Wolynski will oversee all technology resources for the organization, including the recently opened Lighthouse Guild Technology Center, and will develop strategies to bring the latest technological advances
- Euclid Systems Announces Expansion of Leadership Teamhttps://modernod.com/news/euclid-systems-announces-expansion-of-leadership-team/2478845/Euclid Systems has announced expansion of its leadership team. Joseph Boorady, OD, FAAO, appointed to the position of president and chief executive officer in January 2020, brings over 25 years of experience in the ophthalmic industry as an eye care professional, educational leader, entrepreneur